Risk factors associated with pulmonary arterial hypertension in Colombian patients with systemic sclerosis: Review of the literature

Journal of Rheumatology

Volumn 35, Issue 2, 2008, Pages 244-250

  Coral Alvarado, Paola ^a   Rojas Villarraga, Adriana ^b,c   Latorre, María C ^d   Mantilla, Ruben D ^d   Restrepo, José F ^e   Pardo, Aryce L ^a   Chalem, Philippe ^f   Rondón, Federico ^e   Jáuregui, Edwin ^d   Rueda, Juan C ^d   Cañas, Carlos ^g   Hincapie, María E ^h   Pineda Tamayo, Ricardo ^b   Alvarez, Fausto ^a   Iglesias Gamarra, Antonio ^e   Diaz, Francisco J ^a   Anaya, Juan Manuel ^b,c  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b Unidad de Biología Celular y Molecular   (Colombia)

^c UNIVERSIDAD DEL ROSARIO   (Colombia)

^d CAYRE

^e UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^f FIRI

^g FUNDACIÓN VALLE DEL LILI   (Colombia)

^h CIB

Author keywords

Colombia; Pulmonary arterial hypertension; Systemic sclerosis

Indexed keywords

ADULT; ANEMIA; ARTICLE; COLOMBIA; CONFIDENCE INTERVAL; DATA BASE; DYSPHAGIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LOGISTIC REGRESSION ANALYSIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROSTOMIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUESTIONNAIRE; RISK FACTOR; SYSTEMIC SCLEROSIS;

ADULT; AGED; COLOMBIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; ODDS RATIO; PULMONARY FIBROSIS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 39549115711     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
2. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
3. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55.
4. Varga J, Korn JH. Pathogenesis of systemic sclerosis: emphasis on human data. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott, Williams and Wilkins; 2004:63-98.
5. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003;29:335-49.
6. Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine Baltimore 2002;81:154-67.
7. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239-54.
8. Steen VD. Predictors of endstage lung disease in systemic sclerosis. Ann Rheum Dis 2003;62:97-9.
9. McNearney TA, Reveille JD, Fischbach M, et al. Pulmonary involvement in systemic sclerosis: Associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007;57:318-26.
10. Marie I, Levesque H, Hatron PY, Dominique S, Courtois H. Pulmonary involvement in systemic scleroderma. Part II. Isolated pulmonary arterial hypertension, bronchopulmonary cancer, alveolar hemorrhage. Rev Med Interne 1999;20:1017-27.
11. Mukerjee D, St. George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-93.
12. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-800.
13. Wigley FM, Lima JA, Mayes M, McLain D, Chapin JL, Ward-Able C. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists. Arthritis Rheum 2005;52:2125-32.
14. Bolster MB, Silver RM. Lung disease in systemic sclerosis (scleroderma). Baillieres Clin Rheumatol 1993;7:79-97.
15. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
16. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-8.
17. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-9.
18. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology Oxford 2001;40:453-9.
19. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971;75:369-76.
20. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 2003;29:315-33.
21. Vlachoyiannopoulos PG, Dafni UG, Pakas I, Spyropoulou-Vlachou M, Stavropoulos-Giokas C, Moutsopoulos HM. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000;59:359-67.
22. La Montagna G, Sodano A, Capurro V, Malesci D, Valentini G. The arthropathy of systemic sclerosis: a 12 month prospective clinical and imaging study. Skeletal Radiol 2005;34:35-41.
23. Pope JE. Musculoskeletal involvement in scleroderma. Rheum Dis Clin North Am 2003;29:391-408.
24. Schurawitzki H, Stiglbauer R, Graninger W, et al. Interstitial lung disease in progressive systemic sclerosis: high-resolution CT versus radiography. Radiology 1990;176:755-9.
25. Sud A, Gupta D, Wanchu A, Jindal SK, Bambery P. Static lung compliance as an index of early pulmonary disease in systemic sclerosis. Clin Rheumatol 2001;20:177-80.
26. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R. Interpretive strategies for lung function tests. Eur Resp J 2005;26:948-68.
27. Preston IR, Hill NS. Evaluation and management of pulmonary hypertension in systemic sclerosis. Curr Opin Rheumatol 2003;15:761-5.
28. Kahan A, Allanore Y. Primary myocardial involvement in systemic sclerosis. Rheumatology Oxford 2006;45 Suppl 4:iv14-iv17.
29. Boulman N, Slobodin G, Rozenbaum M, Rosner I. Calcinosis in rheumatic diseases. Semin Arthritis Rheum 2005;34:805-12.
30. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2-10.
31. Pizzo G, Scardina GA, Messina P. Effects of a nonsurgical exercise program on the decreased mouth opening in patients with systemic scleroderma. Clin Oral Invest 2003;7:175-8.
32. Naylor WP, Douglass CW, Mix E. The nonsurgical treatment of microstomia in scleroderma: a pilot study. Oral Surg Oral Med Oral Pathol 1984;57:508-11.
33. Czirjak L, Kiss CG, Lovei C, et al. Survey of Raynaud's phenomenon and systemic sclerosis based on a representative study of 10,000 south-Transdanubian Hungarian inhabitants. Clin Exp Rheumatol 2005;23:801-8.
34. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003;29:275-91.
35. Altman RD, Medsger TA Jr, Bloch DA, Michel BA. Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 1991;34:403-10.
36. Meyer O. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006;73:490-4.
37. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42.
38. Silman AJ, Newman J. Epidemiology of systemic sclerosis. Curr Opin Rheumatol 1996;8:585-9.
39. Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC. Racial differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1992;35:216-8.
40. Kuwana M, Okano Y, Kaburaki J, Tojo T, Medsger TA Jr. Racial differences in the distribution of systemic sclerosis-related serum antinuclear antibodies. Arthritis Rheum 1994;37:902-6.
41. Medsger TA Jr. D-penicillamine treatment of lung involvement in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1987;30:832-4.
42. Barnett AJ. Scleroderma (progresive systemic sclerosis): progress and course based on a personal series of 118 cases. Med J Aust 1978;2:129-34.
43. Steen VD, Owens GR, Redmond C, Rodnan GP, Medsger TA Jr. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985;28:882-8.
44. Scorza R, Caronni M, Bazzi S, et al. Post-menopause is the main risk factor for developing isolated pulmonary hypertension in systemic sclerosis. Ann NY Acad Sci 2002;966:238-46.
45. Schachna L, Wigley FM, Chang B, White B, Wise RA, Gelber AC. Age and risk of pulmonary arterial hypertension in scleroderma. Chest 2003;124:2098-104.
46. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997;40:734-42.
47. Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998;114:801-7.
48. Steen VD, Conte C, Owens GR, Medsger TA Jr. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994;37:1283-9.
49. Peters-Golden M, Wise RA, Schneider P, Hochberg M, Stevens MB, Wigley F. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine 1984;63:221-31.
50. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765-70.
51. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of endstage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-50.
52. Schneider PD, Wise RA, Hochberg MC, Wigley FM. Serial pulmonary function in systemic sclerosis. Am J Med 1982;73:385-94.
53. Greenwald GI, Tashkin DP, Gong H, et al. Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med 1987;83:83-92.
54. Konig G, Luderschmidt C, Hammer C, Adelmann-Grill BC, Braun-Falco O, Fruhmann G. Lung involvement in scleroderma. Chest 1984;85:318-24.
55. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006;55:598-602.
56. Plastiras SC, Karadimitrakis SP, Kampolis C, Moutsopoulos HM, Tzelepis GE. Determinants of pulmonary arterial hypertension in scleroderma. Semin Arthritis Rheum 2007;36:392-96.
57. Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131:217-22.
58. Jacobsen S, Ullman S, Shen GQ, Wiik A, Halberg P. Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J Rheumatol 2001;28:2454-9.
59. Morgan C, Knight C, Lunt M, Black CM, Silman AJ. Predictors of endstage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003;62:146-50.
60. Morelli S, Barbieri C, Sgreccia A, et al. Relationship between cutaneous and pulmonary involvement in systemic sclerosis. J Rheumatol 1997;24:81-5.
61. Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology Oxford 2000;39:1269-71.
62. Steen V, Medsger TA Jr. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum 2003;48:516-22.
63. Mukerjee D, St. George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology Oxford 2004;43:461-6.
64. Bull HA, Dowd PM. Endothelin-I in human skin. Dermatology 1993;187:1-5.
65. Imokawa G, Miyagishi M, Yada Y. Endothelin-I as a new melanogen: coordinated expression of its gene and the tyrosinase gene in UVB-exposed human epidermis. J Invest Dermatol 1995;105:32-7.
66. Rubens C, Ewert R, Halank M. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562-9.
67. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, Bois RM. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
68. Trad S, Amoura Z, Beigelman C, et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006;54:184-91.
69. Ebert EC. Esophageal disease in scleroderma. J Clin Gastroenterol 2006;40:769-75.
70. Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001;45:346-54.
71. Schachter LM, Dixon J, Pierce RJ, O'Brien P. Severe gastroesophageal reflux is associated with reduced carbon monoxide diffusing capacity. Chest 2003;123:1932-6.
72. Kinuya K, Nakajima K, Kinuya S, Michigishi T, Tonami N, Takehara K. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement. Ann Nucl Med 2001;15:97-101.
73. Denis P, Ducrotte P, Pasquis P, Lefrancois R. Esophageal motility and pulmonary function in progressive systemic sclerosis. Respiration 1981;42:21-4.
74. Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989;149:589-93.
75. Sjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994;37:1265-82.
76. Schechter AN, Gladwin MT. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N Engl J Med 2003;348:1483-5.
77. Zhang Y, Qui Y, Zhu J, Gao D. Pulmonary hypertension associated with autoimmune hemolytic anemia: A case report. Int J Cardiol 2007;115:e1-e2.
78. Rother R, Bell L, Hillmen P, Gladwin M. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin. JAMA 2005;293:1653-62.
79. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
80. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis - a report from the EULAR Scleroderma Trials And Research (EUSTAR) group data base. Ann Rheum Dis 2007;66:754-63.
81. Chang B, Schachna L, White B, Wigley FM, Wise RA. Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma. J Rheumatol 2006;33:269-74.
82. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001;44:1359-62.
83. Herrick AL, Worthington J. Genetic epidemiology: Systemic sclerosis. Arthritis Res 2002;4:165-8.
84. Zhou X, Tan FK, Wang N, Genome-wide association study for regions of systemic sclerosis susceptibility in a Choctaw Indian population with high disease prevalence. Arthritis Rheum 2003;48:2585-92.
85. Anaya JM, Gomez L, Castiblanco J. Is there a common genetic basis for autoimmune diseases? Clin Dev Immunol 2006;13:185-95.
86. Anaya JM, Corena R, Castiblanco J, Rojas-Villarraga A, Shoenfeld Y. The kaleidoscope of autoimmunity: multiple autoimmune syndromes and familial autoimmunity. Expert Rev Clin Immunol 2007;3:623-35.
87. Magnant J, Diot E. Systemic sclerosis: epidemiology and environmental factors [French}. Presse Med 2006;35:1894-901.